Emily Sheldon‐Waniga

526 total citations
12 papers, 76 citations indexed

About

Emily Sheldon‐Waniga is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Emily Sheldon‐Waniga has authored 12 papers receiving a total of 76 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 5 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Emily Sheldon‐Waniga's work include Chronic Lymphocytic Leukemia Research (4 papers), Hemoglobinopathies and Related Disorders (4 papers) and Virus-based gene therapy research (2 papers). Emily Sheldon‐Waniga is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Hemoglobinopathies and Related Disorders (4 papers) and Virus-based gene therapy research (2 papers). Emily Sheldon‐Waniga collaborates with scholars based in United States, United Kingdom and Spain. Emily Sheldon‐Waniga's co-authors include Dirk Huebner, E. Jane Leonard, Christina S. Baik, Xiaofei Zhou, Gyula Ostoros, David R. Spigel, Tibor Csőszi, Diane R. Mould, Kristiaan Nackaerts and Erin Zagadailov and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Emily Sheldon‐Waniga

12 papers receiving 76 citations

Peers

Emily Sheldon‐Waniga
Izac J. Findlay Australia
Stacey Green United States
Subha Vogeti United States
Hannah M. Jacobs United States
Clémence Virely United Kingdom
Katayoon Kasaian Canada
Friederike Christen Germany
Diala Abd-Rabbo Canada
Joshua Morse United States
Sasi Arunachalam United States
Izac J. Findlay Australia
Emily Sheldon‐Waniga
Citations per year, relative to Emily Sheldon‐Waniga Emily Sheldon‐Waniga (= 1×) peers Izac J. Findlay

Countries citing papers authored by Emily Sheldon‐Waniga

Since Specialization
Citations

This map shows the geographic impact of Emily Sheldon‐Waniga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Sheldon‐Waniga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Sheldon‐Waniga more than expected).

Fields of papers citing papers by Emily Sheldon‐Waniga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Sheldon‐Waniga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Sheldon‐Waniga. The network helps show where Emily Sheldon‐Waniga may publish in the future.

Co-authorship network of co-authors of Emily Sheldon‐Waniga

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Sheldon‐Waniga. A scholar is included among the top collaborators of Emily Sheldon‐Waniga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Sheldon‐Waniga. Emily Sheldon‐Waniga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Kanter, Julie, Melissa A. Kinney, Janet L. Kwiatkowski, et al.. (2024). An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel. Blood. 144(Supplement 1). 511–511. 3 indexed citations
2.
Jaroscak, Jennifer, Julie Kanter, Robert I. Liem, et al.. (2024). Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials. Blood. 144(Supplement 1). 3576–3576. 1 indexed citations
3.
Kanter, Julie, Anjulika Chawla, Alexis A. Thompson, et al.. (2024). Lovotibeglogene Autotemcel Gene Therapy for Sickle Cell Disease: 60 Months Follow-up. 1(Supplement_1). 1 indexed citations
4.
Kanter, Julie, Alexis A. Thompson, Janet L. Kwiatkowski, et al.. (2024). Efficacy and Safety in Patients (Pts) with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up. Transplantation and Cellular Therapy. 30(2). S230–S231. 1 indexed citations
5.
6.
Shimizu, Toshio, Toshihiko Doi, Shunsuke Kondo, et al.. (2018). First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2506–2506. 6 indexed citations
7.
8.
Owonikoko, Taofeek K., Kristiaan Nackaerts, Tibor Csőszi, et al.. (2017). OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 12(1). S261–S262. 17 indexed citations
9.
Kaplan, Jason, Leo I. Gordon, J. Infante, et al.. (2017). TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. Hematological Oncology. 35(S2). 72–74. 5 indexed citations
10.
Zhou, Xiaofei, et al.. (2017). Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. British Journal of Clinical Pharmacology. 84(1). 35–51. 14 indexed citations
11.
Nackaerts, K., Tibor Csőszi, Gyula Ostoros, et al.. (2016). Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC). Annals of Oncology. 27. vi493–vi493. 11 indexed citations
12.
Kaplan, Jason, Leo I. Gordon, Jeffrey R. Infante, et al.. (2016). Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. Blood. 128(22). 624–624. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Izac J. Findlay Breakdown of academic impact, for papers by Stacey Green Breakdown of academic impact, for papers by Subha Vogeti Breakdown of academic impact, for papers by Hannah M. Jacobs Breakdown of academic impact, for papers by Clémence Virely Breakdown of academic impact, for papers by Katayoon Kasaian Breakdown of academic impact, for papers by Friederike Christen Breakdown of academic impact, for papers by Diala Abd-Rabbo Breakdown of academic impact, for papers by Joshua Morse Breakdown of academic impact, for papers by Sasi Arunachalam
Rankless by CCL
2026